Skip to main content
Clinical Trials/KCT0006901
KCT0006901
Recruiting
未知

Seroprevalence of anti-SARS-CoV-2 antibody in response to COVID-19 vaccine in patients with i nflammatory bowel disease SARS-CoV-2

Keimyung University Dongsan Hospital0 sites150 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Keimyung University Dongsan Hospital
Enrollment
150
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational Study
Sex
All

Investigators

Sponsor
Keimyung University Dongsan Hospital

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients who are scheduled to receive SARS\-CoV\-2 vaccine (BNT162b2, mRNA\-1273\) among IBD patients aged 20 to 80 years
  • 2\. Patients who are expected to complete SARS\-CoV\-2 vaccination among IBD patients aged 20 to 80 years
  • 3\. A person who has signed a written consent form after agreeing to the purpose and method of the clinical research
  • 4\. Patients taking 5\-aminosalicylic acid (ASA), immunomodulatory agents, or biological agents (infliximab or vedolizumab) among Crohn's disease/ulcerative colitis patients

Exclusion Criteria

  • 1\. Patients with IBD for whom information on adverse reactions related to vaccination cannot be obtained
  • 2\. Patients with acute illness who have been hospitalized within 4 weeks of starting vaccination
  • 3\. Patients who have had surgery within 3 months
  • 4\. Those who have passed more than 19 weeks after completing the second dose of vaccine
  • 5\. Subjects who do not agree to participate in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials